Your cat was diagnosed with Mammary Carcinoma. 25.4 per 100,000 female cats per year. Third most common feline cancer (after lymphoma and skin cancer). 85-90% malignant — dramatically different from canine (~50% benign). Most common cancer in cats >10 years of age. Compare 7 treatment options for cats including Bilateral Staged Mastectomy, Unilateral Mastectomy, Surgery + Doxorubicin (Adjuvant) — with survival times, costs, and what to expect during treatment.
Pet Cancer Options — Mammary Carcinoma
Feline Oncology Treatment Guide
Mammary Carcinoma
Epithelial
About This Cancer
Mammary carcinoma in cats is a biologically aggressive cancer arising from the milk-producing glands. A critical difference from dogs is that 85–90% of feline mammary tumours are malignant — far higher than the roughly 50% rate in dogs. It is the third most common cancer in cats (after lymphoma and skin tumours) and most frequently affects older, intact (unspayed) females. As in dogs, the risk is dramatically reduced by early ovariohysterectomy. Tumour size is the single most important prognostic factor: tumours smaller than 2 cm carry a significantly better prognosis than larger ones. The cancer tends to spread to the lungs and regional lymph nodes. Siamese cats are overrepresented and may develop the disease at a younger age. Surgery — ideally radical mastectomy (often performed as a staged bilateral procedure) — is the mainstay of treatment, with chemotherapy considered for larger or more advanced tumours.
TNM Staging for Feline Mammary Tumours (Modified)
Clinical TNM staging based on tumour size, lymph node involvement, and distant metastasis. 2025 proposal refines Stage III into IIIA/IIIB/IIIC.
Prognostic Factors(8)
Minimum Workup(8 steps)
Median Survival Time Comparison
How long the average patient survives with each treatment
Each treatment is rated by how much published research supports its use. Solid bars indicate stronger evidence; dashed bars mean less certainty.
Please note: All treatment data is sourced from published peer-reviewed literature. Survival times and cost figures are approximate guides. Your pet's individual factors — including tumour grade, stage, and overall health — will influence outcomes and should guide all treatment decisions. The strength-of-evidence rating reflects how much research exists, not how strongly a treatment is recommended. This tool is designed to help you have informed conversations with your veterinary oncologist, not to replace them. Costs shown are US referral centre estimates and may vary significantly by region.